On April 8, 2019, Progenics Pharmaceuticals, Inc. issued a statement regarding the Schedule 13D filing by Altiva Management Inc., Velan Capital, L.P. and certain of their affiliates disclosing that Velan has nominated 6 candidates to be considered for appointment or election to the Company’s Board of Directors. The Company added that members of Progenics’ Board and management team have had recent discussions with Velan to better understand their views, maintain a constructive dialogue and discuss our plans for growth and value creation. Further, the Company stated that the Nominating and Corporate Governance Committee of the Progenics Board of Directors will consider Velan’s nominees in accordance with the Company’s Director Nominations Policy. The Committee will present its formal recommendation regarding director nominations in the Company’s proxy materials that will be filed with the U.S. SEC.